Vineet Gupta is the Founder and CEO of 149 Bio. Vineet is an expert in the field of integrins and was among the first to identify allosteric agonists as a differentiated therapeutic modality to target integrins and demonstrated the therapeutic efficacy of this modality in human patients.

Vineet is a successful entrepreneur and has taken two startups from concept to exit, where he was the founder CEO. Most recently, his startup Adhaere Pharmaceuticals, Inc was acquired by Gossamer Bio, Inc. Vineet has extensive expertise in the field of integrins, high-throughput drug discovery and therapeutic development, and has been successful in taking compounds from discovery into the clinic. Vineet’s research is focused in the areas or auto-immune disease, kidney disease, cardiovascular diseases and oncology. He is widely published in high-impact peer-reviewed literature and has >50 patents/applications to his credit.  

Vineet received his Master’s of Science in Chemistry from the Indian Institute of Technology, Delhi (IIT Delhi) and his PhD in Chemistry from University of Rochester. He did his post-doctoral studies at The Rockefeller University and at Harvard Medical School. He previously held faculty positions at the Massachusetts General Hospital/Harvard Medical School and at University of Miami. He has also previously worked at various biotech companies. He is also an Endowed Professor and Vice Chair for Innovation in the Department of Internal Medicine at Rush University Medical Center, Chicago, IL and holds The Charles Arthur Weaver Chair for Cancer Research.